MVIC welcomes a new member company in our consortium: Inhaled Delivery Consulting, with CEO Gunilla Petersson.
Dr. Petersson assists clients with development, registration and promotion of inhaled drug delivery technologies and inhaled combination products. Examples from the start in 2023 include evaluation of particle engineering and inhaler technologies, development of powder products, nebulizers, soft mist inhalers, inhaler integrated sensors for disease monitoring, regulatory strategies, technology promotion via conference presentations, expert presentations to health care professionals, intelligence support, competitor analysis.
Her expertise is based on 31 years of pharmaceutical industry experience where she worked as an inhalation expert and line manager in AstraZeneca for 30 years and thereafter as an independent consultant in the field of inhaled drug delivery. The last 7 years in AZ she worked as the Science and Innovation Director of Inhaled Drug Delivery at AstraZeneca, affiliated to the Innovation Strategies and External Liaison, IS&EL.
Topics over the years in industry (AZ) span drug product development (analytical, formulation, device, both small and large molecules), regulatory documentation, regulatory CMC expertise (12 years as board member of EPAG and IPAC-RS), device development, tech transfer, inspections, due diligences, technology scouting and in-licensing, scientific marketing together with commercial department and local marketing companies, competitor analysis, academic collaborations, scientific papers and international conference presentations.
Gunilla Petersson also acts as a board member in MVIC, Senior Adviser in Hcmed (nebulisers), AstraZeneca (pharmaceutical dev.) and Nanoform (particle engineering).